Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations.
Ratings
0 / 5
0 ratings in the last 12 months
5
4
3
2
1
CEO
Dr. Pratik Shah, PhD$206.8M
Market Cap • 23/04/20242017
(há 7 anos)
2021
(3 years ago)
NASDAQ
Listagem
Carlsbad
Sede • California58
N° de Empregados • 2022Valuation
Company FinancialsValuation Indicators
Valuation IndicatorsRetorno Histórico
DSGNSó no Premium...
Visualize o retorno de longo prazo das ações. Dividendos e outros eventos são considerados.